BACKGROUND: It has been proposed that a history of suicide attempts could be a correlate of severe depressive disorder and that suicide attempters (SA) could represent a particular subtype of subjects suffering from major depressive disorder. We investigated clinical and demographic characteristics associated with SA and tested the hypothesis that a history of suicide attempts predicts poor response to antidepressants. METHODS:One-hundred-and-forty-one SA and 670 non-SA subjects with major depressive disorder (MDD) were treated for twelve weeks with escitalopram or nortriptyline in GENDEP, a part-randomized multi-center clinical and pharmacogenetic study. Baseline characteristics were compared using linear and logistic regression. Linear mixed models were used to analyse continuous outcomes during the twelve weeks of follow-up. RESULTS: At baseline, SA subjects suffered from more severe depression (mean Montgomery-Asberg Depression Rating Scale: 30.29 (7.61) vs 28.43 (6.54), p=0.0002), reported higher level of suicidal ideation (1.21 (0.82) vs 0.73 (0.48), p<0.0001), had a younger age of onset and experienced more depressive episodes, had higher harm avoidance scores and poorer socio-demographic environment than non-SA individuals. However, during the twelve weeks of treatment and after adjustment for baseline severity of depression there was no difference in treatment response between SA and non-SA. LIMITATIONS: Due to its retrospective design, it is possible that more severely depressed subjects might report more suicide attempts than less depressed individuals. CONCLUSIONS: While SA differed from non-SA in several clinical and demographic characteristics, the antidepressants were similarly effective in SA as in comparably severely depressed subjects without a history of suicide attempts. Copyright 2009 Elsevier B.V. All rights reserved.
RCT Entities:
BACKGROUND: It has been proposed that a history of suicide attempts could be a correlate of severe depressive disorder and that suicide attempters (SA) could represent a particular subtype of subjects suffering from major depressive disorder. We investigated clinical and demographic characteristics associated with SA and tested the hypothesis that a history of suicide attempts predicts poor response to antidepressants. METHODS: One-hundred-and-forty-one SA and 670 non-SA subjects with major depressive disorder (MDD) were treated for twelve weeks with escitalopram or nortriptyline in GENDEP, a part-randomized multi-center clinical and pharmacogenetic study. Baseline characteristics were compared using linear and logistic regression. Linear mixed models were used to analyse continuous outcomes during the twelve weeks of follow-up. RESULTS: At baseline, SA subjects suffered from more severe depression (mean Montgomery-Asberg Depression Rating Scale: 30.29 (7.61) vs 28.43 (6.54), p=0.0002), reported higher level of suicidal ideation (1.21 (0.82) vs 0.73 (0.48), p<0.0001), had a younger age of onset and experienced more depressive episodes, had higher harm avoidance scores and poorer socio-demographic environment than non-SA individuals. However, during the twelve weeks of treatment and after adjustment for baseline severity of depression there was no difference in treatment response between SA and non-SA. LIMITATIONS: Due to its retrospective design, it is possible that more severely depressed subjects might report more suicide attempts than less depressed individuals. CONCLUSIONS: While SA differed from non-SA in several clinical and demographic characteristics, the antidepressants were similarly effective in SA as in comparably severely depressed subjects without a history of suicide attempts. Copyright 2009 Elsevier B.V. All rights reserved.
Authors: Alexandra Schosser; Amy W Butler; Marcus Ising; Nader Perroud; Rudolf Uher; Mandy Y Ng; Sarah Cohen-Woods; Nick Craddock; Michael J Owen; Ania Korszun; Lisa Jones; Ian Jones; Michael Gill; John P Rice; Wolfgang Maier; Ole Mors; Marcella Rietschel; Susanne Lucae; Elisabeth B Binder; Martin Preisig; Julia Perry; Federica Tozzi; Pierandrea Muglia; Katherine J Aitchison; Gerome Breen; Ian W Craig; Anne E Farmer; Bertram Müller-Myhsok; Peter McGuffin; Cathryn M Lewis Journal: PLoS One Date: 2011-07-05 Impact factor: 3.240
Authors: Y Li; S Shi; F Yang; J Gao; Youhui Li; M Tao; G Wang; K Zhang; C Gao; L Liu; Kan Li; Keqing Li; Y Liu; Xumei Wang; J Zhang; L Lv; Xueyi Wang; Q Chen; J Hu; L Sun; J Shi; Y Chen; D Xie; J Flint; K S Kendler; Z Zhang Journal: Psychol Med Date: 2011-11-30 Impact factor: 7.723
Authors: Caroline W Grant; Angelina R Wilton; Rima Kaddurah-Daouk; Michelle Skime; Joanna Biernacka; Taryn Mayes; Thomas Carmody; Liewei Wang; Konstantinos Lazaridis; Richard Weinshilboum; William V Bobo; Madhukar H Trivedi; Paul E Croarkin; Arjun P Athreya Journal: Front Pharmacol Date: 2022-10-03 Impact factor: 5.988